Aventis Pharma, Themis sign tech deal

MUMBAI: Aventis Pharma and Themis Laboratories have signed a technology transfer agreement for fixed-dose combinations comprising glibenclamide (Daonil) and glimepiride (Amaryl).

These are two best selling products from the Sanofi-Aventis research pipeline with sustained-release metformin through a unique technology developed by Themis Laboratories for the treatment of Type 2 diabetes.

Earlier, both Daonil and Amaryl were available as single - ingredient drugs for the treatment of Type 2 diabetes. However, there was a need to introduce a fixed-dose combination for both drugs with metformin sustained-release formulation through a technology that ensures the requisite bioavailability to help patients needing such a combination therapy.

At 10:53 AM, the Aventis Pharma share was up 0.59% at Rs 1330 on the NSE.